NJGK(SH:600064)2018-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 80.66% to CNY 185.77 million year-on-year[6] - Operating revenue rose by 18.60% to CNY 855.10 million compared to the same period last year[6] - The weighted average return on equity increased by 0.78 percentage points to 1.80%[6] - The company's net profit for Q1 2018 was CNY 218,986,118.30, a significant increase from CNY 112,062,719.78 in the same period last year, representing a growth of 95.4%[35] - Basic and diluted earnings per share for Q1 2018 were CNY 0.240, compared to CNY 0.133 in Q1 2017, reflecting an increase of 80.5%[36] - The operating profit for Q1 2018 was CNY 10,983,056.25, compared to CNY 2,847,677.33 in Q1 2017, marking an increase of 285.5%[37] - The total profit for Q1 2018 was CNY 10,488,386.25, up from CNY 2,854,304.21 in the previous year, showing an increase of 267.5%[37] Cash Flow - Cash flow from operating activities showed an improvement, with a net cash outflow of CNY 161.29 million, significantly better than the previous year's outflow of CNY 643.93 million[6] - The net cash flow from operating activities for Q1 2018 was negative CNY 161,285,791.55, an improvement from negative CNY 643,930,674.92 in Q1 2017[40] - The total cash inflow from operating activities was ¥955,621,826.60, a substantial increase from ¥132,912,833.58 year-over-year[44] - The company reported a net cash decrease of -¥174,795,321.49 for the quarter, contrasting with a net increase of ¥63,723,247.80 in the previous year[44] Assets and Liabilities - Total assets decreased by 1.56% to CNY 25.71 billion compared to the end of the previous year[6] - The company's total assets as of March 31, 2018, amounted to CNY 25,714,168,937.14, down from CNY 26,121,498,581.69 at the beginning of the year[28] - Total liabilities decreased to CNY 14,505,271,725.13 from CNY 15,360,975,784.82 at the start of the year, reflecting a reduction of approximately 5.6%[28] - The company's cash and cash equivalents decreased to CNY 115,565,770.87 from CNY 265,376,399.74, representing a decline of 56.5%[30] - The company's equity attributable to shareholders increased to CNY 10,536,592,029.30 from CNY 10,121,430,535.04, marking a growth of 4.1%[28] Real Estate Performance - The area of completed real estate projects decreased by 84.01% year-on-year, with a total completion area of 38,800 square meters during the reporting period[18] - The contract sales area for real estate was 2,000 square meters, a year-on-year decrease of 98.89%, with a total contract sales amount of 57.50 million yuan, down 90.63% year-on-year[18] - The company has no new real estate project reserves during the reporting period[18] Investment Activities - The net cash flow from investment activities was CNY 89.51 million, a turnaround from a negative cash flow in the previous year[14] - The company’s investment activities generated a net cash inflow due to the maturity of short-term bank wealth management products purchased by its subsidiary[17] - The company plans to transfer 60.04% of its shares in Jiangsu Chenpai Pharmaceutical Group for an estimated price of 780.52 million yuan, pending necessary approvals[22] Shareholder Information - The number of shareholders reached 52,842 by the end of the reporting period[9] Other Financial Metrics - The company reported a significant increase of 305.31% in notes receivable, totaling CNY 293.40 million[13] - The company experienced a 103.66% increase in taxes and surcharges, amounting to CNY 72.75 million[13] - The increase in accounts receivable is primarily due to the increase in notes received from the company's land development transfer business during the period[15] - The increase in other receivables is mainly due to the increase in agency deposits paid for the pharmaceutical sales business during the period[15] - Other comprehensive income after tax for Q1 2018 was CNY 207,164,918.68, down from CNY 444,523,130.09 in the same period last year, a decrease of 53.5%[38] - The total comprehensive income for Q1 2018 was CNY 220,835,125.77, compared to CNY 453,060,200.55 in Q1 2017, indicating a decline of 51.2%[38]